Last reviewed · How we verify
NCT04646902: KYNTOSA
Kynurenine/Tryptophan Ratio in Hypertension Associated to Obstructive Sleep Apnea
trial in Hypertension Secondary in 203 participants. Status unknown.
1 September 2023
Quick facts
| Lead sponsor | Universidade Nova de Lisboa |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 203 |
| Start date | 25 March 2021 |
| Primary completion | 1 September 2023 |
| Estimated completion | 1 March 2024 |
| Sites | 5 locations across Portugal |
Conditions studied
- Hypertension Secondary — all drugs for Hypertension Secondary →
Sponsor
Universidade Nova de Lisboa — full company profile →
Who can join
30 and older, any sex, with Hypertension Secondary. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Obstructive Sleep Apnea (OSA) is an independent risk factor for hypertension (HTN) and the most common cause of resistant HTN. The mechanisms underlying OSA-associated HTN are not completely understood. This is crucial to find novel therapeutic targets of OSA-associated HTN. The Aryl Hydrocarbon Receptor (AHR) is a cytosolic transcription factor that has been linked with the pathogenesis of HTN. This study aims to evaluate the role of endogenous ligands of AHR such as kynurenine in discriminating patients with OSA-associated HTN. For that aim, a case-control study will be performed in patients with and without hypertension exposed and not exposed to OSA. Kynurenine and other metabolites will be quantified in urine and serum samples.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
The aryl hydrocarbon receptor: a rehabilitated target for therapeutic immune modulation.
Polonio CM, McHale KA, Sherr DH, Rubenstein D, et al · · 2025 · cited 41× · PMID 40247142 · DOI 10.1038/s41573-025-01172-x
Verify or expand the search:
- PubMed search for NCT04646902
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Universidade Nova de Lisboa trials
Trials by the same sponsor.
- NCT05593835 — Multimorbidity Management Supported by a Digital Platform · NA · not yet recruiting
- NCT06794515 — cGMP: Metabolism and Appetite Modulation · NA · not yet recruiting
- NCT05788952 — The Role of Intestinal and Vaginal Microbiota, Estrogenic Activity, Metabolic Profile & Nutritional Status in Endometrio · unknown
- NCT05375487 — The Effect of Natural Carbonated Mineral Water Consumption on Gastrointestinal Transit and Gut Microbiota - A Randomized · NA · completed
- NCT05840627 — Acute Satiety and Metabolic Response of Daily Consumption of a Fruit Juice · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04646902 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Universidade Nova de Lisboa
- Last refreshed: 7 December 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04646902.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing